Concise review: Defining and targeting myeloma stem cell-like cells

Stem Cells

Volumn 32, Issue 5, 2014, Pages 1067-1073

  Abe, Masahiro ^a   Harada, Takeshi ^a   Matsumoto, Toshio ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Cancer stem cells; Clonogenic cells; Multiple myeloma; Myeloma niche

Indexed keywords

ADENOSINE TRIPHOSPHATE; BORTEZOMIB; BREAST CANCER RESISTANCE PROTEIN; CHEMOKINE RECEPTOR CXCR4; CYCLOPAMINE; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 3; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PLERIXAFOR; RITUXIMAB; STROMAL CELL DERIVED FACTOR 1; TELOMERASE;

CANCER CELL CULTURE; CANCER STEM CELL; CELL DIFFERENTIATION; CELL SUBPOPULATION; CELL SURVIVAL; CITRIC ACID CYCLE; CLONOGENESIS; COLONY FORMATION; CYTOTOXICITY; GENE EXPRESSION; GENE SEQUENCE; GLYCOLYSIS; HUMAN; IMMUNOGLOBULIN GENE; MEMORY CELL; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; REVIEW; SOMATIC HYPERMUTATION; STEM CELL NICHE; ANIMAL; BIOLOGICAL MODEL; CELL CLONE; GENETICS; METABOLISM; PATHOLOGY; TUMOR MICROENVIRONMENT;

ANIMALS; CELL DIFFERENTIATION; CLONE CELLS; HUMANS; MODELS, BIOLOGICAL; MULTIPLE MYELOMA; NEOPLASTIC STEM CELLS; STEM CELL NICHE; TUMOR MICROENVIRONMENT;

EID: 84898930013     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.1643     Document Type: Review

References (71)

1. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994; 367: 645-648.
2. Kvinlaug BT, Huntly BJ,. Targeting cancer stem cells. Expert Opin Ther Targets 2007; 11: 915-927.
3. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983-3988.
4. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature 2004; 432: 396-401.
5. O'Brien CA, Pollett A, Gallinger S, et al. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007; 445: 106-110.
6. Bakkus MH, Heirman C, Van Riet I, et al. Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation. Blood 1992; 80: 2326-2335.
7. Vescio RA, Cao J, Hong CH, et al. Myeloma Ig heavy chain V region sequences reveal prior antigenic selection and marked somatic mutation but no intraclonal diversity. J Immunol 1995; 155: 2487-2497.
8. Sahota SS, Leo R, Hamblin TJ, et al. Myeloma VL and VH gene sequences reveal a complementary imprint of antigen selection in tumor cells. Blood 1997; 89: 219-226.
9. Pilarski LM, Jensen GS,. Monoclonal circulating B cells in multiple myeloma. A continuously differentiating, possibly invasive, population as defined by expression of CD45 isoforms and adhesion molecules. Hematol Oncol Clin North Am 1992; 6: 297-322.
10. Billadeau D, Ahmann G, Greipp P, et al. The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell. J Exp Med 1993; 178: 1023-1031.
11. Bergsagel PL, Smith AM, Szczepek A, et al. In multiple myeloma, clonotypic B lymphocytes are detectable among CD19+ peripheral blood cells expressing CD38, CD56, and monotypic Ig light chain. Blood 1995; 85: 436-447.
12. Chen BJ, Epstein J,. Circulating clonal lymphocytes in myeloma constitute a minor subpopulation of B cells. Blood 1996; 87: 1972-1976.
13. Szczepek AJ, Seeberger K, Wizniak J, et al. A high frequency of circulating B cells share clonotypic Ig heavy-chain VDJ rearrangements with autologous bone marrow plasma cells in multiple myeloma, as measured by single-cell and in situ reverse transcriptase-polymerase chain reaction. Blood 1998; 92: 2844-2855.
14. Matsui W, Huff CA, Wang Q, et al. Characterization of clonogenic multiple myeloma cells. Blood 2004; 103: 2332-2336.
15. Boucher K, Parquet N, Widen R, et al. Stemness of B-cell progenitors in multiple myeloma bone marrow. Clin Cancer Res 2012; 18: 6155-6168.
16. Kirshner J, Thulien KJ, Martin LD, et al. A unique three-dimensional model for evaluating the impact of therapy on multiple myeloma. Blood 2008; 112: 2935-2945.
17. Pilarski LM, Belch AR,. Clonotypic myeloma cells able to xenograft myeloma to nonobese diabetic severe combined immunodeficient mice copurify with CD34 (+) hematopoietic progenitors. Clin Cancer Res 2002; 8: 3198-3204.
18. Matsui W, Wang Q, Barber JP, et al. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res 2008; 68: 190-197.
19. Hamburger A, Salmon SE,. Primary bioassay of human myeloma stem cells. J Clin Invest 1977; 60: 846-854.
20. Chaidos A, Barnes CP, Cowan G, et al. Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma. Blood 2013; 121: 318-328.
21. Yaccoby S, Epstein J,. The proliferative potential of myeloma plasma cells manifest in the SCID-hu host. Blood 1999; 94: 3576-3582.
22. Yata K, Yaccoby S,. The SCID-rab model: A novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells. Leukemia 2004; 18: 1891-1897.
23. Hosen N, Matsuoka Y, Kishida S, et al. CD138-negative clonogenic cells are plasma cells but not B cells in some multiple myeloma patients. Leukemia 2012; 26: 2135-2141.
24. Kim D, Park CY, Medeiros BC, et al. CD19-CD45 low/- CD38 high/CD138+ plasma cells enrich for human tumorigenic myeloma cells. Leukemia 1038; 26: 2530-2537.
25. Paino T, Ocio EM, Paiva B, et al. CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype. Haematologica 2012; 97: 1110-1114.
26. Trepel M, Martens V, Doll C, et al. Phenotypic detection of clonotypic B cells in multiple myeloma by specific immunoglobulin ligands reveals their rarity in multiple myeloma. Plos One 2012; 7: e31998.
27. Challen GA, Little MH,. A side order of stem cells: The SP phenotype. Stem Cells 2006; 24: 3-12.
28. Ho MM, Ng AV, Lam S, et al. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res 2007; 67: 4827-4833.
29. Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. Cancer Res 2007; 67: 1030-1037.
30. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007; 445: 111-115.
31. Bonnet D, Dick JE,. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730-737.
32. Loh YS, Mo S, Brown RD, et al. Presence of Hoechst low side populations in multiple myeloma. Leuk Lymphoma 2008; 49: 1813-1816.
33. Jakubikova J, Adamia S, Kost-Alimova M, et al. Lenalidomide targets clonogenic side population in multiple myeloma: Pathophysiologic and clinical implications. Blood 2011; 117: 4409-4419.
34. Ikegame A, Ozaki S, Tsuji D, et al. Small molecule antibody targeting HLA class I inhibits myeloma cancer stem cells by repressing pluripotency- associated transcription factors. Leukemia 2012; 26: 2124-2134.
35. Gupta PB, Fillmore CM, Jiang G, et al. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 2011; 146: 633-644.
36. Chaffer CL, Brueckmann I, Scheel C, et al. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci USA 2011; 108: 7950-7955.
37. He K, Xu T, Goldkorn A,. Cancer cells cyclically lose and regain drug-resistant highly tumorigenic features characteristic of a cancer stem-like phenotype. Mol Cancer Ther 2011; 10: 938-948.
38. Raje N, Roodman GD,. Advances in the biology and treatment of bone disease in multiple myeloma. Clin Cancer Res 2011; 17: 1278-1286.
39. Abe M,. Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma. Int J Hematol 2011; 94: 334-343.
40. Yaccoby S,. Advances in the understanding of myeloma bone disease and tumour growth. Br J Haematol 2010; 149: 311-321.
41. Peinado H, Lavotshkin S, Lyden D,. The secreted factors responsible for pre-metastatic niche formation: Old sayings and new thoughts. Semin Cancer Biol 1016; 21: 139-146.
42. Hu J, Van Valckenborgh E, Menu E, et al. Understanding the hypoxic niche of multiple myeloma: Therapeutic implications and contributions of mouse models. Dis Model Mech 2012; 5: 763-771.
43. Martin SK, Diamond P, Gronthos S, et al. The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma. Leukemia 2011; 25: 1533-1542.
44. Asosingh K, De Raeve H, de Ridder M, et al. Role of the hypoxic bone marrow microenvironment in 5T2MM murine myeloma tumor progression. Haematologica 2005; 90: 810-817.
45. Yaccoby S,. The phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation into an immature, resilient, and apoptosis-resistant phenotype. Clin Cancer Res 2005; 11: 7599-7606.
46. Azab AK, Runnels JM, Pitsillides C, et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood 2009; 113: 4341-4351.
47. Beider K, Begin M, Abraham M, et al. CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple myeloma tumor growth. Exp Hematol 2011; 39: 282-292.
48. Buchakjian MR, Kornbluth S,. The engine driving the ship: Metabolic steering of cell proliferation and death. Nat Rev Mol Cell Biol 11: 715-727.
49. Kondoh H,. Cellular life span and the Warburg effect. Exp Cell Res 2008; 314: 1923-1928.
50. Cairns RA, Harris IS, Mak TW,. Regulation of cancer cell metabolism. Nat Rev Cancer 2011; 11: 85-95.
51. Nakano A, Miki H, Nakamura S, et al. Up-regulation of hexokinaseII in myeloma cells: Targeting myeloma cells with 3-bromopyruvate. J Bioenerg Biomembr 2012; 44: 31-38.
52. Birsoy K, Wang T, Possemato R, et al. MCT1-mediated transport of a toxic molecule is an effective strategy for targeting glycolytic tumors. Nat Genet 2013; 45: 104-108.
53. Fletcher JI, Haber M, Henderson MJ, et al. ABC transporters in cancer: More than just drug efflux pumps. Nat Rev Cancer 2010; 10: 147-156.
54. Ding XW, Wu JH, Jiang CP,. ABCG2: A potential marker of stem cells and novel target in stem cell and cancer therapy. Life Sci 86: 631-637.
55. Nakano A, Tsuji D, Miki H, et al. Glycolysis inhibition inactivates ABC transporters to restore drug sensitivity in malignant cells. Plos One 2011; 6: e27222.
56. Kimura N, Kawai S, Kinoshita Y, et al. 2D7 diabody bound to the alpha2 domain of HLA class I efficiently induces caspase-independent cell death against malignant and activated lymphoid cells. Biochem Biophys Res Commun 2004; 325: 1201-1209.
57. Sekimoto E, Ozaki S, Ohshima T, et al. A single-chain Fv diabody against human leukocyte antigen-A molecules specifically induces myeloma cell death in the bone marrow environment. Cancer Res 2007; 67: 1184-1192.
58. Brennan SK, Wang Q, Tressler R, et al. Telomerase inhibition targets clonogenic multiple myeloma cells through telomere length-dependent and independent mechanisms. PLoS One 2010; 5: 0012487.
59. Kapoor P, Greipp PT, Morice WG, et al. Anti-CD20 monoclonal antibody therapy in multiple myeloma. Br J Haematol 2008; 141: 135-148.
60. Jin L, Hope KJ, Zhai Q, et al. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 2006; 12: 1167-1174.
61. Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-111.
62. Derksen PW, Tjin E, Meijer HP, et al. Illegitimate WNT signaling promotes proliferation of multiple myeloma cells. Proc Natl Acad Sci USA 2004; 101: 6122-6127.
63. Peacock CD, Wang Q, Gesell GS, et al. Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proc Natl Acad Sci USA 2007; 104: 4048-4053.
64. Nefedova Y, Sullivan DM, Bolick SC, et al. Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy. Blood 2008; 111: 2220-2229.
65. Sukhdeo K, Mani M, Zhang Y, et al. Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma. Proc Natl Acad Sci USA 2007; 104: 7516-7521.
66. Boyer LA, Lee TI, Cole MF, et al. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 2005; 122: 947-956.
67. Jaenisch R, Young R,. Stem cells, the molecular circuitry of pluripotency and nuclear reprogramming. Cell 2008; 132: 567-582.
68. Miki T, Yasuda SY, Kahn M,. Wnt/beta-catenin signaling in embryonic stem cell self-renewal and somatic cell reprogramming. Stem Cell Rev 2011; 21: 21.
69. Marson A, Foreman R, Chevalier B, et al. Wnt signaling promotes reprogramming of somatic cells to pluripotency. Cell Stem Cell 2008; 3: 132-135.
70. Jundt F, Probsting KS, Anagnostopoulos I, et al. Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells. Blood 2004; 103: 3511-3515.
71. Mirandola L, Apicella L, Colombo M, et al. Anti-Notch treatment prevents multiple myeloma cells localization to the bone marrow via the chemokine system CXCR4/SDF-1. Leukemia 2013; 27: 1558-1566.